Clinical trial data readouts and regulatory milestones for lead programs in cardiovascular and neurological indications
New strategic partnerships or expansion of existing collaborations with major pharmaceutical companies
Genetic target validation announcements from Compass platform identifying novel disease modifiers
FDA regulatory decisions including IND clearances and breakthrough therapy designations
low - Pre-revenue biotech companies are largely insulated from GDP fluctuations as their value derives from clinical pipeline potential rather than current economic activity. However, broader risk appetite and venture capital availability can be affected by economic conditions, impacting ability to raise capital and sector valuations.
Rising interest rates negatively impact biotech valuations through two mechanisms: (1) higher discount rates reduce NPV of distant future cash flows from pipeline assets, and (2) increased competition from risk-free rates makes speculative biotech investments less attractive. The company's strong current ratio (17.70) and positive operating cash flow ($0.1B) provide some insulation from financing pressures, but equity valuation multiples compress in rising rate environments.
Clinical trial failure risk inherent to drug development, particularly for novel genetic modifier-based mechanisms without prior clinical validation
Regulatory pathway uncertainty for precision medicine approaches requiring companion diagnostics or genetic screening
Increasing competition in genetic medicine space from well-funded players including Vertex, Regeneron, and emerging gene therapy companies
growth - Attracts speculative biotech investors focused on clinical pipeline optionality and platform technology value rather than current earnings. The 266.6% one-year return and 251.2% six-month return indicate momentum-driven trading, while the $2.3B market cap on $0.2B revenue (11.5x P/S) reflects growth expectations. High volatility profile typical of clinical-stage biotech with binary event risk around trial readouts.
1 signal unavailable — limited data for this stock
Distribution pattern detected. More selling days than accumulation over the past 20 sessions. Not a conducive environment for a squeeze.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
ANALYST ESTIMATES
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $3.1M $2.9M–$3.3M | — | -$3.12 | — | ±12% | High9 |
FY2026(current) | $20.0M $18.8M–$21.2M | ▲ +540.0% | -$2.69 | — | ±16% | High6 |
FY2027 | $13.9M $12.1M–$15.7M | ▼ -30.5% | -$3.18 | — | ±34% | High7 |
INSTITUTIONAL OWNERSHIP
MAZE News
About
No company information available
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
MAZE◀ | $25.56 | -3.29% | $1.4B | — | -10000.0% | — | 1500 |
| $66.13 | -5.07% | $13.0B | — | +12626.1% | -14525.8% | 1500 | |
| $94.92 | -3.79% | $12.6B | — | +3288.2% | -4239.0% | 1500 | |
| $523.69 | -3.00% | $12.1B | — | +43205.3% | -3008.0% | 1500 | |
| $227.72 | -1.30% | $11.7B | — | +6554.5% | -2868.8% | 1500 | |
| $57.90 | -0.86% | $11.2B | 50.3 | +1459.3% | 147.7% | 1500 | |
| $76.67 | -3.79% | $10.8B | — | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -3.01% | — | 50.3 | +340421.2% | -4085.6% | 1500 |